1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1007/s11926-003-0085-6" target="_blank" rel="noreferrer">http://doi.org/10.1007/s11926-003-0085-6</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Bisphosphonate mechanism of action
Publisher
An entity responsible for making the resource available
Current Rheumatology Reports
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
Subject
The topic of the resource
Humans; Clodronate; Apoptosis; Bone Resorption/metabolism; Diphosphonates/chemistry/metabolism/pharmacology; Mevalonic Acid/antagonists & inhibitors; Osteoclasts/drug effects/metabolism/physiology; Osteoporosis/metabolism
Creator
An entity primarily responsible for making the resource
Reszka AA; Rodan GA
Description
An account of the resource
The nitrogen-containing bisphosphonates (N-BPs), alendronate and risedronate, are the only pharmacologic agents shown to prevent spine and nonvertebral fractures associated with postmenopausal and glucocorticoid-induced osteoporosis. At the tissue level, this is achieved through osteoclast inhibition, which leads to reduced bone turnover, increased bone mass, and improved mineralization. The molecular targets of bisphosphonates (BPs) have recently been identified. This review will discuss the mechanism of action of BPs, focusing on alendronate and risedronate, which are the two agents most widely studied. They act on the cholesterol biosynthesis pathway enzyme, farnesyl diphosphate synthase. By inhibiting this enzyme in the osteoclast, they interfere with geranylgeranylation (attachment of the lipid to regulatory proteins), which causes osteoclast inactivation. This mechanism is responsible for N-BP suppression of osteoclastic bone resorption and reduction of bone turnover, which leads to fracture prevention.
2003
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1007/s11926-003-0085-6" target="_blank" rel="noreferrer">10.1007/s11926-003-0085-6</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
2003
Apoptosis
Backlog
Bone Resorption/metabolism
Clodronate
Current Rheumatology Reports
Diphosphonates/chemistry/metabolism/pharmacology
Humans
Journal Article
Mevalonic Acid/antagonists & inhibitors
Osteoclasts/drug effects/metabolism/physiology
Osteoporosis/metabolism
Reszka AA
Rodan GA